logo
ScreenersREIT EarningsREIT SectorsIndustriesMarketplace
Logo

Eterna Therapeutics Inc.

ERNA

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, aā€¦ read more

Healthcare

Biotechnology

34 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.31

Price

+3.97%

$0.05

$1.26

Previous Close

$1.29

Open

Premium

52w Discount
Market Cap

$10.282m

Small

Price/Earnings

0x

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$1k

-99.8%

1y CAGR

+218.7%

3y CAGR

+164.0%

5y CAGR
Earnings

-$18.340m

+58.8%

1y CAGR

-11.6%

3y CAGR

+11.3%

5y CAGR
EPS

-$1.33

+15.3%

1y CAGR

+42.1%

3y CAGR

+53.0%

5y CAGR
Book Value

$3.570m

$6.172m

Assets

$2.602m

Liabilities

$552k

Debt
Debt to Assets

8.9%

-0.1x

Debt to EBITDA
Free Cash Flow

-$9.436m

+41.8%

1y CAGR

+22.1%

3y CAGR

+19.1%

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in USD.
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.